Ripple Therapeutics

We are pleased to announce evaluation and licensing agreements with Glaukos Corporation. “This is the first of what we believe will be a number of transactions using our technology platform in concert with partners’ APIs to create sustained release implants which will benefit patients with extended duration and improved safety” -Tom Reeves, President & CEO, Ripple Therapeutics #ophthalmology #glaucoma #retinaldisease #patientsinsight #drugdelivery #transformingvision #healthcareinnovation

Associate Professor Hemal Mehta presented Efficacy and safety of the low dose dexamethasone IBE-814 IVT implant for diabetic macular edema and retinal vein occlusion: Results of a first-in-human Phase 2 trial at #Euretina2024. #ophthalmology #drugdelivery #retinaveinocclusion #diabeticmacularedema #diabetes #healthcareinnovation #keepingpatientsinsight

We are pleased to announce a collaboration and option-to-license agreement with AbbVie. "We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics. By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma." -Tom Reeves, President & CEO, Ripple Therapeutics #Opthalmology #Drugdelivery #Glaucoma #Healthcareinnovation #PatientsinSight #researchanddevelopment #Nextgenerationtherapies

Wishing our co-ops all the best in their next chapter. Thank you Nicole Watson, Riya Panchal and Meera Mistry for your significant contributions. #WaterlooU #McMasterU #opthalmology #drugdelivery #healthcareinnovation #labwork

We are proud of our VP Operations, Fraidianie Sévigné, for supporting education and knowledge transfer initiatives, globally. Fraidiane is hosting a series of webinars on Ophthalmic Drug Formulations and Technology Advancements with Ophthalmology students at the University of Parakou in the Republic of Benin, West Africa. This new initiative follows a recent advisor assignment in Ghana, where she trained Women Entrepreneurs and the staff at Social Enterprise Ghana on compliance. Thanks to University of Toronto Entrepreneurship's H2i for extending the Medtech Entrepreneur Accelerator Program to Africa and selecting our VP Operations as the Lead Mentor for the African Level 3 start-ups.

Our Chief Technology Officer, Wendy Naimark, is speaking MaRS Discovery District Impact Health. Wednesday June 12th. Startup Pitch: Biotech Ventures (10:50-11:50) #startup #biotechnology #impacthealth2024 #drugdelivery #ophthalmology #healthcareinnovation

Pleased to partner with University of Waterloo to find co-op talent using their rank/match process to help narrow down top selections. We look at not only a student’s experience but also consider a student’s enthusiasm and passion. “In most cases, you can train a student on the technical side of what you do. What we look for is self-motivation. A student that will reach out and let their supervisor know when they have time to help in other areas beyond their core responsibilities,” - Greg Whitton Kaitlyn Brushey Riya Panchal Meera Mistry Blanca Keohan #drugdelivery #MedicinalChemistry #Biochemistry #Chemistry #nanotechnolgy #engineering #researchanddevelopment

Madeline Simpson and Ian Parrag presented results of RIPPLE-1 @ARVO2024. RIPPLE-1 was a first-in-human phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety, efficacy, and durability of two dosage regimens of the IBE-814 IVT Implant. The IBE-814 IVT Implant enables sustained dexamethasone delivery to the retina. The implant is administered by intravitreal injection using a 30G needle. Results from RIPPLE-1 showed reduced CST and improved or stable BCVA at Month 6 in all cohorts of participants with diabetic macular edema (DME) and retinal vein occlusion (RVO), a reduction in treatment burden compared to pre-study and safety comparable to other intravitreal steroids. #ophthalmology #drugdelivery #sustainedrelease #keepingpatientsinsight #visionforthefuture #healthcareinnovation #clinicaltrial

Great week at #ARVO2024. Thanks to everyone who attended our Poster Presentations. Associate Professor Hemal Mehta Kyle Battiston Ian Parrag #visionforthefuture #keepingpatientsinsight #ophthalmology #drugdelivery #healthcareinnovation

Ripple is excited to be presenting (1 On Demand and 3 Poster Sessions) at #ARVO2024 this week. *Presentation On Demand Ocular tolerability and IOP-lowering evaluation of the RTC-620 intracameral implant in normotensive beagle dogs Ike Ahmed, Kyle Battiston, Shadi Taghavi, Mahta Massoud, Eamon Kelly, Hans Fischer, Dimitra Louka, Matthew Statham, Jonny Day, Adam Daley, Ian Parrag, Wendy Naimark *Presentation Poster Session May 7 8:30AM -10:15AM (PDT) IBE-814 IVT Implants reduce treatment burden in subjects with DME and RVO due to sustained-release of dexamethasone: An analysis of the First-in-Human Phase 2 RIPPLE-1 trial Kelli-anne Wootton, Gillian Mackey, Madeline Simpson, Joseph Reiz, Wendy Naimark *Presentation Poster Session May 7 3:30PM-5:15PM (PDT) Chronic ocular tolerability and pharmacodynamics of the RTC-1119 intracameral implant in normotensive beagle dogs Kyle Battiston, Shadi Taghavi, Hans Fischer, Matthew Statham, Jonny Day, Emily Baldwin, Adam Daley, Ian Parrag, Wendy Naimark *Presentation Poster Session May 9 11:45AM-1:30PM (PDT) Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial Hemal Mehta, Kelli-anne Wootton, Madeline Simpson, Gillian Mackey, Wendy Naimark #visionforthefuture #keepingpatientsinsight #ophthalmology #drugdelivery #healthcareinnovation